TC Home

The only technical publication dedicated to readers who formulate, manufacture, or package solid dosage forms.

Slide background
Slide background
  • May 19, 2021

SOMERSET, NJ—Catalent has signed an agreement with Canadian biotech company Cybin to apply Catalent’s Zydis orally disintegrating tablet (ODT) technology to deliver Cybin’s novel deuterated tryptamine, a potential therapy for treatment-resistant psychiatric disorders. Zydis creates a freeze-dried tablet that rapidly dissolves in the mouth without water, which would allow pre-gastric delivery of deuterated tryptamine and prevent first pass metabolism, improving the drug’s pharmacokinetic profile. The project commenced in April and will involve feasibility studies of ODT doses with varying quantities of deuterated tryptamine along with other excipients.